Environmental Engineering Reference
In-Depth Information
90. Anderson PM, Tomaras M, McConnell K (2010) Mifamurtide in osteosarcoma—a practical
review. Drugs Today (Barc) 46(5):327-337
91. Groll AH, Silling G, Young C, Schwerdtfeger R, Ostermann H, Heinz WJ, Gerss J, Kolve H,
Lanvers-Kaminsky C, Vieira Pinheiro JP, Gammelin S, Cornely OA, Wuerthwein G (2010)
Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal
amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients.
Antimicrob Agents Chemother 54(10):4143-4149. doi:
10.1128/AAC.00425-10
92. Portillo J, Kamar N, Melibary S, Quevedo E, Bergese S (2014) Safety of liposome extended-
release bupivacaine for postoperative pain control. Front Pharmacol 5:90
93. Malaekeh-Nikouei B, Malaekeh-Nikouei M, Oskuee RK, Ramezani M (2009) Preparation,
characterization, transfection efficiency, and cytotoxicity of liposomes containing
oligoamine-modified cholesterols as nanocarriers to Neuro2A cells. Nanomedicine 5
(4):457-462. doi:
10.1016/j.nano.2009.02.001
94. Sun X, Chen J, Gu X, Liang W, Wang J (2014) Efficacy and toxicity of cisplatin liposomes
modified with polyethylenimine. Pharmazie 69(4):281-286
95. Xie M, Chen Y, Wu L (2013) Preparation of doxorubicin-hydrochloride nanoliposomes by
ethanol injection-pH gradient method and their safety evaluation. J Nanosci Nanotechnol 13
(1):216-221
96. Dadgar N, Alavi SE, Esfahani MK, Akbarzadeh A (2013) Study of toxicity effect of
pegylated nanoliposomal artemisinin on breast cancer cell line. Indian J Clin Biochem 28
(4):410-412. doi:
10.1007/s12291-013-0306-3
97. Esfahani MK, Alavi SE, Movahedi F, Alavi F, Akbarzadeh A (2013) Cytotoxicity of
liposomal paclitaxel
in breast cancer cell
line mcf-7.
Indian J Clin Biochem 28
(4):358-360. doi:
10.1007/s12291-013-0296-1
98. Ait-Oudhia S, Mager DE, Straubinger RM (2014) Application of pharmacokinetic and
pharmacodynamic analysis to the development of liposomal formulations for oncology.
Pharmaceutics 6(1):137-174. doi:
10.3390/pharmaceutics6010137
99. Needham D, Anyarambhatla G, Kong G, Dewhirst MW (2000) A new temperature-sensitive
liposome for use with mild hyperthermia: characterization and testing in a human tumor
xenograft model. Cancer Res 60(5):1197-1201
100. Lindner LH, Eichhorn ME, Eibl H, Teichert N, Schmitt-Sody M, Issels RD, Dellian M (2004)
Novel temperature-sensitive liposomes with prolonged circulation time. Clin Cancer Res 10
(6):2168-2178
101. Langer R (1998) Drug delivery and targeting. Nature 392(6679 Suppl):5-10
102. Deepa K, Singha S, Panda T (2014) Doxorubicin nanoconjugates. J Nanosci Nanotechnol
14(1):892-904
103. Li L, ten Hagen TL, Schipper D, Wijnberg TM, van Rhoon GC, Eggermont AM, Lindner LH,
Koning GA (2010) Triggered content release from optimized stealth thermosensitive lipo-
somes using mild hyperthermia. J Control Release 143(2):274-279. doi:
10.1016/j.jconrel.
104. Chan JM, Zhang L, Yuet KP, Liao G, Rhee JW, Langer R, Farokhzad OC (2009)
PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials
30(8):1627-1634. doi:
10.1016/j.biomaterials.2008.12.013
105. Ning M, Guo Y, Pan H, Chen X, Gu Z (2005) Preparation, in vitro and in vivo evaluation of
liposomal/niosomal gel delivery systems
for clotrimazole. Drug Dev Ind Pharm
31(4-5):375-383
106. Haley B, Frenkel E (2008) Nanoparticles for drug delivery in cancer treatment. Urol Oncol
26(1):57-64. doi:
10.1016/j.urolonc.2007.03.015
107. Choi SJ, Oh JM, Choy JH (2010) Biocompatible nanoparticles intercalated with anticancer
drug for target delivery: pharmacokinetic and biodistribution study. J Nanosci Nanotechnol
10(4):2913-2916
108. Nobs L, Buchegger F, Gurny R, All´mann E (2004) Current methods for attaching targeting
ligands to liposomes and nanoparticles. J Pharm Sci 93(8):1980-1992
